Batabulin

N/A

Report date: 2022/11/25 17:57:47
NME

Base Information

Drug NameBatabulin
Drug Alias Name巴他布林batabulinumbatabulinabatabulineBatabulin sodium +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursLung NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineSingapore +[13] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteTularik Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLung NeoplasmsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksKEGG